{"id":2822,"date":"2025-08-18T16:00:22","date_gmt":"2025-08-18T20:00:22","guid":{"rendered":"https:\/\/halopharma.com\/?page_id=2822"},"modified":"2025-12-10T13:15:10","modified_gmt":"2025-12-10T18:15:10","slug":"news","status":"publish","type":"page","link":"https:\/\/halopharma.com\/fr\/who-we-are\/news\/","title":{"rendered":"Actualit\u00e9s et \u00e9v\u00e9nements"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u00c9v\u00e9nements \u00e0 venir<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tCPHI Europe\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\n\t\t\n\t\t\tRejoignez-nous\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\tf\u00e9vrier 24, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tContract Pharma\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\n\t\t\n\t\t\tRejoignez-nous\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\tf\u00e9vrier 24, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Derni\u00e8res nouvelles<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats Over $30 million investment plan underway to establish sterile vial, prefilled syringe, and cartridge manufacturing in Whippany, NJ Lee Karras (previously CEO of Noramco) named Halo Pharma\u2019s CEO to lead next phase of expansion Whippany, NJ \u2013 May 1, 2026 \u2013 Halo Pharma (the \u201cCompany\u201d), a leading CDMO partner to the pharmaceutical industry and previous division of Noramco Group, is now operating as a standalone business following Siegfried\u2019s acquisition of Noramco Group\u2019s small molecule API assets. Owned and supported by funds advised by SK Capital, the Company serves as a dedicated, specialized platform focused on developing and manufacturing products for its pharmaceutical customers. Halo Pharma has invested heavily to support its active expansion into sterile product development and fill\/finish services to support growing customer demand. \u201cBuilding on decades of supporting pharmaceutical and healthcare clients, Halo Pharma is entering an exciting new phase as an independent CDMO,\u201d said Lee Karras, CEO of Halo Pharma. \u201cWe are focused on expanding our capabilities to meet evolving customer needs, including the launch of sterile injectable manufacturing at our Whippany,<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tmai 1, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tApotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey \u2014 April 14, 2026 \u2013 Apotex Corp. today announced that it has secured a strategic sterile filling partnership with Halo Pharmaceuticals through an investment that provides Apotex with access to a significant portion of the overall sterile injectable filling capacity currently being installed and qualified at Halo\u2019s Whippany, New Jersey facility. This access is intended to support Apotex\u2019s sterile injectable manufacturing network and signals a strong investment in sterile U.S.-based manufacturing, infrastructure and research and development capabilities. The partnership aligns with Apotex\u2019s Journey of Health strategy and its broader focus on strengthening domestic manufacturing operations. The arrangement enables Apotex to access near-term sterile filling capacity and offers an alternative to a greenfield development approach, providing operational flexibility as part of its global manufacturing strategy. Halo Pharmaceuticals is a strategically aligned organization providing development and manufacturing services across a range of dosage forms, including sterile injectable formats. Through this collaboration, Apotex brings its strong sterile processing experience, regulatory readiness expertise, and commercialization capabilities while securing access to vial and pre-filled syringe filling capacity. The partnership builds upon the existing Apotex-Halo relationship, which currently includes non-sterile<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tavril 14, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tParenteral and Sterile Fill-Finish Development and Manufacturing Trends\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral\/sterile drug product manufacturers.<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tavril 10, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory approvals Halo Pharma, with sites in Whippany, NJ and Mirabel QC, will remain as a stand-alone company with a focus on growth as a drug product contract development and manufacturing organization (CDMO) Lee Karras will become CEO of Halo Pharma after the transaction closes The divestiture allows for more focus on drug product services in North America as Halo expands into more complex drug product manufacturing services such as sterile fill\/finish Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses to Siegfried. Halo Pharma was purchased by the Noramco Group from Cambrex in 2023. With the sale of the API related assets of the Noramco Group, Halo will serve as a dedicated platform for drug product CDMO services. Halo\u2019s sterile CDMO business is expected to be online in the second half of 2026 with a state-of-the-art Groninger UFVN FlexFill<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tjanvier 27, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor\u00ae to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor\u00ae, a versatile roller compactor that enhances the company\u2019s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products. The investment reinforces Halo Pharma\u2019s position as a reliable partner for both development and commercial manufacturing as it allows for seamless scale up from Halo Whippany\u2019s Gerties Mini-Pactor\u00ae currently used for development, clinical and small scall commercial manufacturing. The Macro-Pactor is expected to be online in the first quarter of 2026. Its high throughput, superior dry-granulation performance, improved powder flow, and reduced variability will significantly expand Halo Pharma\u2019s dry-granulation capabilities. It will improve formulation flexibility, process predictability, and granule quality. This technology is especially beneficial for the development of moisture-sensitive APIs, high-drug-load formulations, poor-flowing powders, potent compounds, and modified-release products within Halo Pharma\u2019s portfolio. \u201cOne of the major advantages of adding the Macro-Pactor is that the process parameters established during<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\td\u00e9cembre 16, 2025\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma nomme Laurent Malgouyres directeur du site de Mirabel, au Canada.\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 14 octobre 2025 \u2013 Laurent Malgouyres rejoint Halo fort de plus de 14 ans d'exp\u00e9rience op\u00e9rationnelle dans l'industrie pharmaceutique. En tant que directeur de site, il supervisera les op\u00e9rations du site de production cGMP de Halo \u00e0 Mirabel. Halo Pharma, une CDMO de premier plan sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la fabrication de produits pharmaceutiques, a nomm\u00e9 Laurent Malgouyres au poste de directeur de son site cGMP de Mirabel, au Qu\u00e9bec, Canada. Dans ses nouvelles fonctions, M. Malgouyres supervisera la production, la qualit\u00e9 et la performance globale du site. Fort de plus de 14 ans d'exp\u00e9rience dans l'industrie pharmaceutique, il occupait r\u00e9cemment le poste de vice-pr\u00e9sident des op\u00e9rations chez Omega Laboratories\/Juno Pharmaceuticals au Canada. Auparavant, il a occup\u00e9 des postes de direction chez Pharmascience, o\u00f9 il a g\u00e9r\u00e9 des sites agr\u00e9\u00e9s par la FDA et Sant\u00e9 Canada employant plus de 200 personnes. Tout au long de sa carri\u00e8re, il a men\u00e9 avec succ\u00e8s des initiatives visant \u00e0 accro\u00eetre la capacit\u00e9 de production, \u00e0 mettre en \u0153uvre des processus d'efficacit\u00e9 op\u00e9rationnelle et \u00e0 r\u00e9aliser d'importants projets d'investissement. \u201c Laurent a fait ses preuves en mati\u00e8re de cr\u00e9ation d'\u00e9quipes autonomes et performantes, tout en favorisant une culture d'excellence op\u00e9rationnelle, d'am\u00e9lioration continue et de d\u00e9veloppement humain, valeurs qui correspondent \u00e0 nos convictions et objectifs fondamentaux chez Halo Pharma \u201d, d\u00e9clare Lee Karras, PDG de Noramco, soci\u00e9t\u00e9 m\u00e8re de Halo Pharma. \u201c Son exp\u00e9rience et sa vision seront essentielles \u00e0 la poursuite de notre d\u00e9veloppement. \u00bb<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\t20 octobre 2025\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Upcoming Events Latest News<\/p>","protected":false},"author":24,"featured_media":0,"parent":3362,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-2822","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2822"}],"version-history":[{"count":37,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822\/revisions"}],"predecessor-version":[{"id":3878,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822\/revisions\/3878"}],"up":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/3362"}],"wp:attachment":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}